Shares of AtriCure, Inc. (NASDAQ:ATRC – Get Free Report) have been given a consensus rating of “Hold” by the twelve analysts that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $55.70.
A number of brokerages have issued reports on ATRC. BTIG Research upped their price objective on shares of AtriCure from $55.00 to $63.00 and gave the stock a “buy” rating in a research report on Monday, October 12th. Freedom Capital cut shares of AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 2nd. Raymond James Financial set a $52.00 target price on AtriCure in a research note on Tuesday, July 21st. Citizens Jmp upped their target price on AtriCure from $52.00 to $68.00 and gave the company a “market outperform” rating in a report on Wednesday, October 21st. Finally, Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a report on Wednesday, October 21st.
Read Our Latest Report on ATRC
AtriCure Trading Up 0.7%
NASDAQ ATRC opened at $61.51 on Wednesday. The company has a fifty day moving average price of $54.70 and a 200-day moving average price of $37.85. AtriCure has a 1 year low of $25.36 and a 1 year high of $61.78.
Insider Buying and Selling at AtriCure
In other news, insider Salvatore Privitera sold 4,519 shares of AtriCure stock in a transaction on Wednesday, September 23rd. The stock was sold at an average price of $60.00, for a total transaction of $271,140.00. Following the sale, the insider directly owned 142,745 shares in the company, valued at $8,564,700. The trade was a 3.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Karl S. Dahlquist sold 9,370 shares of the business’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $48.89, for a total transaction of $458,099.30. Following the completion of the transaction, the insider directly owned 87,319 shares in the company, valued at $4,269,025.91. This trade represents a 9.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 37,686 shares of company stock valued at $1,898,756 in the last ninety days. 4.00% of the stock is owned by corporate insiders.
Institutional Trading of AtriCure
Large investors have recently added to or reduced their stakes in the stock. Verdence Capital Advisors LLC bought a new stake in AtriCure in the 3rd quarter valued at about $231,000. Sterling Capital Management LLC lifted its holdings in AtriCure by 841.1% during the third quarter. Sterling Capital Management LLC now owns 1,647 shares of the medical device company’s stock valued at $93,000 after purchasing an additional 1,472 shares during the last quarter. Yousif Capital Management LLC purchased a new stake in AtriCure during the third quarter valued at about $762,000. Net Worth Advisory Group bought a new position in AtriCure during the third quarter worth about $305,000. Finally, State of Alaska Department of Revenue boosted its position in AtriCure by 265.6% during the third quarter. State of Alaska Department of Revenue now owns 10,497 shares of the medical device company’s stock worth $589,000 after purchasing an additional 7,626 shares during the period. Hedge funds and other institutional investors own 99.11% of the company’s stock.
About AtriCure
AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.
The company’s product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.
Featured Stories
- Five stocks we like better than AtriCure
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.
